Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III, Randomized, Double Blind and Placebo Controlled Study of Once Daily BI 201335 120 mg for 24 Weeks and BI 201335 240 mg for 12 Weeks in Combination With Pegylated Interferon Alpha and Ribavirin in Treatment Naive Patients With Genotype 1 Chronic Hepatitis C Infection.

Next Previous
Search
Trial Profile

A Phase III, Randomized, Double Blind and Placebo Controlled Study of Once Daily BI 201335 120 mg for 24 Weeks and BI 201335 240 mg for 12 Weeks in Combination With Pegylated Interferon Alpha and Ribavirin in Treatment Naive Patients With Genotype 1 Chronic Hepatitis C Infection.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 08 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Faldaprevir (Primary) ; Peginterferon alfa; Ribavirin
  • Indications Hepatitis C
  • Focus Registrational; Therapeutic Use
  • Acronyms STARTVerso-2
  • Sponsors Boehringer Ingelheim

Most Recent Events

  • 17 Sep 2015 Endpoints has been changed and timeframe of primary end point has been changed from 12 weeks to 12 weeks post treatment, up to 60 weeks. Number of arms has changed from 3 to 4 as reported by ClinicalTrials.gov record.
  • 16 Apr 2014 According to ClinicalTrials.gov record, status changed from active, no longer recruiting to completed.
  • 13 Apr 2014 Pooled pharmacokinetic-response analysis presented at the 49th Annual Meeting of the European Association for the Study of the Liver.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top